公开(公告)号：US09642998B2

公开(公告)日：2017-05-09

申请号：US14641089

申请日：2015-03-06

Applicant: MEDICIS PHARMACEUTICAL CORPORATION

Inventor： Michael T. Nordsiek ,  Kodumudi S. Balaji

IPC: A61K31/00 ,  A61M35/00 ,  B05B11/00 ,  A61K9/00 ,  A61K9/06 ,  A61K31/4745 ,  A61K47/10

CPC classification number: A61M35/003 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/06 ,  A61K31/4745 ,  A61K47/10 ,  B05B11/0037 ,  B05B11/0038 ,  B05B11/00416 ,  B05B11/00446 ,  B05B11/3001 ,  B05B11/3042 ,  B05B11/3047

Abstract: The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).

公开(公告)号：US20200276182A1

公开(公告)日：2020-09-03

申请号：US16268230

申请日：2019-02-05

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC: A61K31/4745 ,  A61K31/47 ,  A61K31/437 ,  A61K47/10 ,  A61K9/06 ,  A61K9/00 ,  A61K9/70 ,  A61K47/12 ,  A61K47/14

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

公开(公告)号：US11318130B2

公开(公告)日：2022-05-03

申请号：US16268230

申请日：2019-02-05

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC: A61K31/4745 ,  A61K31/47 ,  A61K31/437 ,  A61K47/10 ,  A61K9/06 ,  A61K9/00 ,  A61K9/70 ,  A61K47/12 ,  A61K47/14

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

公开(公告)号：US20140206735A1

公开(公告)日：2014-07-24

申请号：US14136280

申请日：2013-12-20

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Kodumudi S. Balaji

IPC: A61K31/4164

CPC classification number: A61K31/4164 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/32 ,  A61K47/38

Abstract: The present disclosure provides aqueous-based gel formulations of metronidazole useful for a variety of purposes, including topical application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with rosacea.

Abstract translation: 本公开提供了用于各种目的的甲硝唑的水性凝胶制剂，包括局部施用作为治疗患有和/或诊断为酒渣鼻的个体的治疗方法。

公开(公告)号：US10238644B2

公开(公告)日：2019-03-26

申请号：US15187751

申请日：2016-06-20

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC: A61K9/00 ,  A61K9/06 ,  A61K9/70 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K31/437 ,  A61K31/4745

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.